Departmental Seminar

Dosimetry of targeted radionuclide therapy: the good, the bad and the exciting!

Dr Boon Quan Lee
GenesisCare, Theranostics

Clinical applications of targeted radionuclide therapy (TRT) have progressed significantly in the past two decades. From the invention of 90Y-based Selective Internal Radiation Therapy (SIRT) for liver tumours to the success of 177Lu-based targeted beta therapy for neuroendocrine cancer and the ongoing development of 177Lu- and 225Ac-based targeted therapy for prostate cancer, TRT has attracted significant interests and offers a new hope for some hard-to-treat metastatic diseases.

It is becoming evident that patient-specific absorbed dose assessment should become routine, like other forms of radiation therapy, to improve the correlations between administered activity and the clinical outcome and enable better understanding of dose-response relationship in TRT. However, there are many hurdles to overcome before patient-specific dosimetry can be adapted into clinical routines for better patient care.

This talk will discuss the challenges in performing TRT dosimetry and the ongoing research efforts to tackle these problems as well as future research directions that could improve the value of dosimetry.

Updated:  23 September 2021/ Responsible Officer:  Director, RSPhys/ Page Contact:  Physics Webmaster